SEC	Form	4
-----	------	---

Γ

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1	Check this box if no longer subject to
L	Section 16. Form 4 or Form 5 obligations
1	may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense co 10b5-1(c). See Instruc							
1. Name and Address of Reporting Person <sup>*</sup> Shetty Ajit			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Actinium Pharmaceuticals, Inc.</u> [ATNM]		tionship of Reporting Person( all applicable) Director	s) to Issuer 10% Owner	
, , , , , , , , , , , , , , , , , , ,	(First) (Middle) INIUM PHARMACEUTICALS, INC.,		3. Date of Earliest Transaction (Month/Day/Year) 03/31/2025		Officer (give title below)	Other (specify below)	
C/O ACTINIUM PHARMACEUTICALS, INC., 100 PARK AVE., 23RD FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv X			
(Street)					Form filed by More than O	ne Reporting Person	
NEW YORK,	NY	10017					
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)	str. (A) or Price			5. Amount of Securities Beneficially Owned Following Reported 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	<ul> <li>Transaction(s)</li> <li>(Instr. 3 and 4)</li> </ul>		(Instr. 4)

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$47.4 <sup>(1)</sup>	03/31/2025		D			2,500	(1)	03/28/2027	Common Stock	2,500	\$0 <sup>(1)</sup>	0	D	
Stock Option (Right to Buy)	\$23.49 <sup>(1)</sup>	03/31/2025		D			2,500	(1)	07/13/2028	Common Stock	2,500	\$0 <sup>(1)</sup>	0	D	
tock Option (Right to Buy)	\$6.96 <sup>(1)</sup>	03/31/2025		D			8,333	(1)	07/12/2029	Common Stock	8,333	\$0 <sup>(1)</sup>	0	D	
Stock Option (Right to Buy)	\$9.55 <sup>(1)</sup>	03/31/2025		D			8,333	(1)	08/12/2030	Common Stock	8,333	\$0 <sup>(1)</sup>	0	D	
Stock Option (Right to Buy)	\$6.07 <sup>(1)</sup>	03/31/2025		D			18,351	(1)	09/01/2031	Common Stock	18,351	\$0 <sup>(1)</sup>	0	D	
Stock Option (Right to Buy)	\$4.96 <sup>(1)</sup>	03/31/2025		D			72,156	(1)	07/01/2032	Common Stock	72,156	\$0 <sup>(1)</sup>	0	D	
Stock Option (Right to Buy)	\$5 <sup>(1)</sup>	03/31/2025		D			70,311	(1)	12/28/2033	Common Stock	70,311	\$0 <sup>(1)</sup>	0	D	

Explanation of Responses:

1. Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value \$0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration.



04/02/2025

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.